7.25
Tango Therapeutics Inc stock is traded at $7.25, with a volume of 1.30M.
It is down -3.54% in the last 24 hours and down -15.24% over the past month.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
See More
Previous Close:
$7.495
Open:
$7.48
24h Volume:
1.30M
Relative Volume:
0.50
Market Cap:
$806.64M
Revenue:
$24.30M
Net Income/Loss:
$-145.57M
P/E Ratio:
-5.4511
EPS:
-1.33
Net Cash Flow:
$-149.17M
1W Performance:
-20.98%
1M Performance:
-15.24%
6M Performance:
+395.21%
1Y Performance:
+21.92%
Tango Therapeutics Inc Stock (TNGX) Company Profile
Name
Tango Therapeutics Inc
Sector
Industry
Phone
(857) 320-4900
Address
201 BROOKLINE AVENUE, BOSTON
Compare TNGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
TNGX
Tango Therapeutics Inc
|
7.25 | 1.00B | 24.30M | -145.57M | -149.17M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.57 | 108.04B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
475.81 | 60.75B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
583.26 | 61.26B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
825.21 | 50.32B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
316.55 | 34.14B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-17-24 | Initiated | Jefferies | Buy |
| Apr-04-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-24 | Initiated | Piper Sandler | Overweight |
| Dec-08-23 | Initiated | B. Riley Securities | Buy |
| Oct-20-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-20-21 | Initiated | SVB Leerink | Outperform |
View All
Tango Therapeutics Inc Stock (TNGX) Latest News
Tango Therapeutics stock gains as Cantor Fitzgerald reiterates Overweight rating - Investing.com
How to build a dashboard for Tango Therapeutics Inc. stockJuly 2025 Selloffs & Low Drawdown Investment Strategies - newser.com
Is Tango Therapeutics Inc. stock entering bullish territoryChart Signals & High Conviction Buy Zone Picks - newser.com
Tango Therapeutics Inc. stock trend outlook and recovery pathWeekly Profit Analysis & Trade Opportunity Analysis Reports - newser.com
Ranking Tango Therapeutics Inc. among high performing stocks via toolsJuly 2025 News Drivers & Entry and Exit Point Strategies - newser.com
Why Tango Therapeutics Inc. stock is trending among retail tradersMarket Sentiment Summary & Technical Entry and Exit Tips - newser.com
Using AI based signals to follow Tango Therapeutics Inc.2025 Market Outlook & Proven Capital Preservation Tips - newser.com
Multi asset correlation models including Tango Therapeutics Inc.2025 Investor Takeaways & Reliable Volume Spike Alerts - newser.com
Tango Therapeutics Inc. (TNGX) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Guggenheim Maintains Tango Therapeutics (TNGX) Buy Recommendation - Nasdaq
Guggenheim Maintains Buy Rating and Raises Price Target for TNGX - GuruFocus
What analysts say about Tango Therapeutics Inc stockHigh Yield Income Stocks & Low Risk Trading Plans - earlytimes.in
Guggenheim raises Tango Therapeutics stock price target on promising cancer drug data - Investing.com
Tango Therapeutics price target raised to $12 from $10 at Guggenheim - TipRanks
Tango Therapeutics announces $225 million financing - The Pharma Letter
Form 424B5 Tango Therapeutics, Inc. - StreetInsider
Tango Therapeutics prices $210 million stock offering By Investing.com - Investing.com Nigeria
Tango Therapeutics Inc Stock (TNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tango Therapeutics Inc Stock (TNGX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Third Rock Ventures IV, L.P. | 10% Owner |
Sep 25 '25 |
Sale |
8.02 |
500,000 |
4,008,500 |
13,863,975 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):